Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.56 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.40 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918641 | 0.86 | FPR2 (0.47) | FPR2HSD17B3TLK2F7HPGD | |
| SCHEMBL4640751 | 0.80 | L3MBTL1 (0.42) | FPR2HSD17B3TLK2HPGDSMN1; SMN2 | |
| SCHEMBL4912835 | 0.75 | HSD17B3 (0.39) | FPR2HSD17B3HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL4642757 | 0.73 | HSD17B3 (0.44) | FPR2HSD17B3L3MBTL1 | |
| SCHEMBL5597243 | 0.72 | HSD17B3 (0.46) | FPR2HSD17B3 | |
| SCHEMBL21698095 | 0.71 | FPR2 (1.00) | FPR2 | |
| SCHEMBL17286102 | 0.71 | FPR2 (1.00) | FPR2 | |
| SCHEMBL4642325 | 0.71 | HSD17B3 (0.47) | HSD17B3 | |
| SCHEMBL18748246 | 0.71 | HSD17B3 (0.56) | HSD17B3HPGDSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4911780 | 0.71 | HSD17B3 (0.40) | HSD17B3HPGDSMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | FPR2 343/4885HSD17B3 2044/4885TLK2 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.